In this publication, ModiQuest describes the discovery of novel therapeutic anti-citrullinated protein antibodies (tACPAs) that prevent the onset and/or exacerbation of inflammation and that prevent or strongly reduce the occurrence of swelling and joint damage, using a collagen antibody-induced arthritis mouse model. The ACPAs discovered by ModiQuest are directed against a citrullinated epitope in histone-2A protein in man and mouse.
ModiQuest has made this discovery using its proprietary antibody discovery technology platforms M-Fuse™ (highly efficient hybridoma electrofusion technology), M-Select™ (B-cell selection technology for low immunogenic or multiple antigen targets) and M-Phage™ (proprietary phase display libraries). All three technology platforms are also used by ModiQuest’s service business, ModiQuest Research BV, for custom antibody lead generation in third party service projects.
“The novel tACPA leads we have discovered offer a new way to contribute to the treatment of rheumatoid arthritis, and we are today in discussions with a number of pharmaceutical companies to progress the tACPA leads into clinical development”, says Dr. Jos Raats, CEO of ModiQuest. “The discovery of these antibody leads again demonstrates the huge potential of our M-Fuse™, M-Select™ and M-Phage™ technologies for the discovery of novel therapeutic and diagnostic antibodies against low-immunogenic targets.”